David Kiragu
Internal Medicine · Chicago, ILNPI 1982860367
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,670 and has fallen 92.9% since, to $118 in 2025.
Across 171 payments — averaging $12.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$322
- Pfizer$185
- Lilly USA, LLC$177
- AstraZeneca$167
- GSK$166
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$137
- plus $989 from 21 others
What the payments were for
- Food & beverage$2,136100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $322 |
| Pfizer | 19 | $185 |
| Lilly USA, LLC | 17 | $177 |
| AstraZeneca | 13 | $167 |
| GSK | 11 | $166 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $137 |
| Merck | 11 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $108 |
| Amgen | 6 | $104 |
| Boehringer Ingelheim | 7 | $101 |
| Eisai Inc. | 5 | $87 |
| Astellas Pharma US Inc | 3 | $56 |
| Johnson & Johnson | 4 | $54 |
| Sanofi-aventis U.S. LLC | 4 | $52 |
| Novartis | 3 | $42 |
| Amarin Pharma, Inc. | 3 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Radius Health, Inc. | 2 | $29 |
| AbbVie(2 entities) | 2 | $29 |
| Organon | 1 | $23 |
| Bausch Health US, LLC | 1 | $16 |
| Viiv Healthcare Company | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Zealand Pharma US, Inc. | 1 | $11 |
| Therapeuticsmd, Inc. | 1 | $11 |
How this compares
$2,143 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 11 | $146 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 11 | $69 |
| Carvedilol | 16 | $59 |
| Furosemide | 17 | $57 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Chicago
- Merle DiamondChicago$1.1M
- Robert KushnerChicago$516K
- Romeo UrsuaChicago$420K
- Peter O DonnellChicago$318K
- George UrbanChicago$258K
- Kristen PallokChicago$256K
- George NissanChicago$252K
- Luke LaffinChicago$162K
- Daniel CatenacciChicago$161K
- Hiren ShahChicago$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.